Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study

被引：0
|
作者：
Popat, Sanjay [1 ]
Ramalingam, Suresh [2 ]
Zhou, Caicun [3 ]
Kim, Tae [4 ]
Yang, James [5 ]
Riely, Gregory [6 ]
Mekhail, Tarek [7 ]
Nguyen, Danny [8 ]
Campelo, Maria Rosario Garcia [9 ]
Felip, Enriqueta [10 ]
Misch, Daniel [11 ]
Kaur, Manmit [12 ]
Bunn, Veronica [12 ]
Lin, Huamao [12 ]
Zhang, Pingkuan [12 ]
Janne, Pasi [13 ]
机构：
[1] Royal Marsden Hosp, London, England
[2] Emory Univ, Atlanta, GA USA
[3] Shanghai Pulm Hosp, Shanghai, Peoples R China
[4] Seoul Natl Univ Hosp, Seoul, South Korea
[5] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[6] Mem Sloan Kettering Canc Ctr, New York, NY USA
[7] AdventHlth Orlando, Orlando, FL USA
[8] City Hope Natl Med Ctr, Duarte, CA USA
[9] Complejo Hosp Univ A Coruna, La Coruna, Spain
[10] Vall dHebron Univ Hosp, Barcelona, Spain
[11] Lungenklin Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany
[12] Takeda Dev Ctr Amer Inc, Lexington, MA USA
[13] Dana Farber Canc Inst, Boston, MA USA
来源：
LUNG CANCER | 2023年 / 178卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
81
引用
收藏
页码：S35 / S35
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of poziotinib in treatment-naive HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4
    Sun, S.
    Prelaj, A.
    Baik, C.
    Le, X.
    Garassino, M.
    Wollner, M.
    Haura, E.
    Piotrowska, Z.
    Socinski, M.
    Dreiling, L.
    Bhat, G.
    Lebel, F.
    Cornelissen, R.
    ANNALS OF ONCOLOGY, 2022, 33 : S13 - S13
  • [42] Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results
    Wang, Mengzhao
    Fan, Yun
    Sun, Meili
    Wang, Yongsheng
    Zhao, Yanqiu
    Jin, Bo
    Hu, Ying
    Han, Zhigang
    Song, Xia
    Liu, Anwen
    Tang, Kejing
    Ding Cuimin
    Liang, Li
    Wu, Lin
    Gao, Junzhen
    Wang, Jianghong
    Cheng, Ying
    Zhou, Jianying
    He, Yong
    Zheng, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] PRO-CTCAE Analysis of Mobocertinib in EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Garcia Campelo, M. R.
    Zhou, C.
    Ramalingam, S. S.
    Lin, H. M.
    Kim, T. M.
    Riely, G. J.
    Mekhail, T.
    Nguyen, D.
    Biber, J.
    Romero, H.
    Goodman, E.
    Popat, S.
    Janne, P. A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S487 - S488
  • [44] Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Updated results.
    Saltos, Andreas Nicholas
    Tanvetyanon, Tawee
    Haura, Eric B.
    Creelan, Ben C.
    Antonia, Scott Joseph
    Shafique, Michael Rahman
    Zheng, Hong
    Dai, Wenjie
    Chen, Zhihua
    Saller, James Joseph
    Tchekmedyian, Nishan
    Goas, Kristen
    Thapa, Ram
    Boyle, Theresa A.
    Chen, Dung-Tsa
    Beg, Amer A.
    Gray, Jhanelle Elaine
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [45] REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
    Nishio, Makoto
    Yu, Helena Alexandra
    Besse, Benjamin
    Cheng, Ying
    Tan, Daniel Shao-Weng
    Wei, Li
    Wacheck, Volker
    Heymach, John
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : TPS219 - TPS219
  • [46] Understanding the diagnostic and treatment landscape in EGFRm advanced non-small cell lung cancer (aNSCLC) patients with exon 20 insertion mutations (Ex20ins)
    Bailey, H.
    Nasirova, F.
    Sermon, J.
    Rodrigues, B.
    Khela, K.
    Hall, J.
    Last, M. J.
    Penton, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S975 - S976
  • [47] Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients.
    Le, Xiuning
    Goldman, Jonathan Wade
    Clarke, Jeffrey Melson
    Tchekmedyian, Nishan
    Piotrowska, Zofia
    Chu, David
    Bhat, Gajanan
    Lebel, Francois M.
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] Real-World Treatment Outcomes of Amivantamab in Pre-Approval Access (PAA) Participants with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations (ex20ins)
    Sabari, J.
    Kim, T. M.
    Spira, A.
    Lee, S. H.
    Chang, G. C.
    Shih, J. -Y.
    Hochmair, M. J.
    Schioppa, C. A.
    Schioppa, C. A.
    Panaccione, A.
    Rose, J. B.
    Chioda, M.
    Mahadevia, P.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E23 - E23
  • [49] Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins)
    Kim, T. M.
    Lee, S-H.
    Chang, G-C.
    Shih, J-Y.
    Hochmair, M. J.
    Sabari, J. K.
    Spira, A. I.
    Schioppa, C. A.
    Rose, J. B.
    Chioda, M.
    Panaccione, A.
    Mahadevia, P.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2022, 33 : S48 - S48
  • [50] Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.
    Yang, James Chih-Hsin
    Wang, Mengzhao
    Mitchell, Paul
    Fang, Jian
    Nian, Weiqi
    Chiu, Chao-Hua
    Zhou, Jianying
    Zhao, Yanqiu
    Su, Wu-Chou
    Camidge, D. Ross
    Yang, Tsung-Ying
    Zhu, Viola Weijia
    Millward, Michael
    Fan, Yun
    Huang, Wen Tsung
    Cheng, Ying
    Jiang, Liyan
    Zheng, Li
    Ye, Xiuhui
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345